文献速递骨质疏松与钙磷/甲状旁腺糖尿病

鸢尾素与甲状旁腺激素相互作用:从基础研究到原发性甲状旁腺功能亢进症的临床证据

A Novel Interplay Between Irisin and PTH: From Basic Studies to Clinical Evidence in Hyperparathyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本研究探讨鸢尾素与甲状旁腺激素(PTH)的相互作用。体外实验显示特立帕肽下调肌管FNDC5表达,重组鸢尾素下调成骨细胞PTH受体mRNA。横断面研究纳入26例原发性甲状旁腺功能亢进症(PHPT)绝经后女性和31例年龄/BMI匹配对照,发现PHPT组鸢尾素水平显著降低。

要点

  • 特立帕肽通过自身受体下调肌管FNDC5表达并激活Erk1/2磷酸化。
  • 重组鸢尾素使成骨细胞PTH受体mRNA表达下调50%(P<0.001)。
  • PHPT绝经后女性鸢尾素水平显著低于匹配对照(4.5±1.1 vs 12±5.2 µg/mL,P<0.001)。

核心结论

  • 临床前发现提示PTH与鸢尾素代谢存在相互作用,PHPT绝经后女性鸢尾素浓度显著降低似乎证实了这一点。

研究设计与样本

  • 体外实验:C2C12肌管接受短期和持续10-10 M特立帕肽处理,MC3T3-E1成骨细胞接受100 ng/mL重组鸢尾素处理8小时。
  • 横断面开放标签试验:纳入26例PHPT绝经后女性和31例年龄/BMI匹配且钙磷代谢正常的对照者。

主要发现

  • 特立帕肽通过自身受体显著下调肌管FNDC5表达,并激活Erk1/2磷酸化。
  • 重组鸢尾素使成骨细胞PTH受体mRNA表达下调50%(P<0.001)。
  • PHPT组鸢尾素显著低于年龄/BMI匹配对照(4.5±1.1 vs 12±5.2 µg/mL;P<0.001)。
  • PHPT组中鸢尾素与骨密度或PTH无显著相关性。

关键数值与推荐

  • 重组鸢尾素使PTH受体mRNA表达下调50%(P<0.001)。
  • PHPT组鸢尾素为4.5±1.1 µg/mL,对照组为12±5.2 µg/mL(P<0.001)。

临床怎么用

  • PHPT患者评估时需关注鸢尾素水平降低及其与骨代谢的潜在关联。
  • PTH与鸢尾素的相互作用可能为代谢性骨病提供新的治疗靶点。

局限性

  • 横断面设计无法确定因果关系。
  • PHPT组样本量较小(26例)。
  • 未报告鸢尾素与骨密度或PTH在PHPT组中的显著相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Irisin is a hormonelike molecule that is cleaved and secreted by an unknown protease from fibronectin type III domain-containing protein 5 (FNDC5). It ameliorates bone status and muscle atrophy and influences energy homeostasis. PTH exerts several metabolic effects that may interact with the effects of irisin. OBJECTIVES: To test the hypothesis that irisin and PTH mutually affect their biological action, we evaluated FNDC5 mRNA and protein expression in myotubes treated with PTH (1-34) and parathyroid hormone receptor (PTH-r) mRNA expression in osteoblasts treated with r-irisin. To confirm the in vivo impact of PTH on irisin, we compared irisin serum concentrations in postmenopausal women with primary hyperparathyroidism (PHPT) and control subjects. DESIGN AND INTERVENTION: C2C12 myotubes were treated with short-term and continuous 10-10 M teriparatide and MC3T3-E1 osteoblasts with 100 ng/mL r-irisin for 8 hours. In a cross-sectional open-label trial, we enrolled 26 postmenopausal women with PHPT and 31 age-/body mass index (BMI)‒matched control subjects without impairment of calcium/phosphate metabolism. RESULTS: Teriparatide treatment on myotubes significantly downregulated FNDC5 expression by acting through its own receptor, which in turn activated Erk11/2 phosphorylation. r-Irisin led to a 50% downregulation of PTH-r mRNA expression compared with untreated cells (P < 0.001). Irisin was significantly lower in the PHPT group than in age-/BMI-matched controls (4.5 ± 1.1 vs 12 ± 5.2 µg/mL; P < 0.001). No significant correlation between irisin and bone mineral density or PTH was recorded in the PHPT group. CONCLUSION: Preclinical findings suggest the existence of an interplay between PTH and irisin metabolism that seems to be confirmed by the significant reduction of irisin concentration in postmenopausal women with PHPT.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Palermo A, Sanesi L, Colaianni G, et al. A Novel Interplay Between Irisin and PTH: From Basic Studies to Clinical Evidence in Hyperparathyroidism. J Clin Endocrinol Metab. 2019. PMID: 30759249. doi:10.1210/jc.2018-02216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。